Will Ebiefung

About the Author Will Ebiefung

Will Ebiefung studied finance and accounting at the University of Tennesee. He works as a freelance investment analyst focusing on equities with market caps below $100 million. In addition to writing, Will is a full-time investor focusing on web properties and debt-based securities.

Making Sense of Advanced Micro Devices, Inc.’s (AMD) Earnings

Advanced Micro Devices, Inc. (NASDAQ:AMD) cratered today, losing around 20% of its market cap after a disappointing earnings report.

The ‘New Era’ of DryShips Inc. (DRYS)

April 28, 2017, marked the “new era” of DryShips Inc. (NASDAQ:DRYS) according to the company’s CEO, George Economou in a press release reporting …

Apple Inc. (AAPL) Boosts Margins; Here’s How

Apple Inc. (NASDAQ:AAPL) is struggling with weak top line growth.

DryShips Inc. (DRYS) Pays Down 15.2 Million in Long-Term Debt; What’s Next?

DryShips Inc. (NASDAQ:DRYS) has announced the repayment of its outstanding commercial loan facility of $15.

Micron Technology, Inc. (MU): An Objective Look at the Fundamentals

Micron Technology, Inc.’s (NASDAQ:MU) stock is up over 155% in twelve months while the S&P 500 only moved 14% in the same time-frame.

Valeant Pharmaceuticals Intl Inc (VRX): A Company in Existential Crisis

  Valeant Pharmaceuticals Intl Inc (NYSE:VRX) will be reporting earnings next month, and if Valeant’s earnings come in short, the guidance management provided …

Tesla Inc (TSLA): China Is a Huge Risk but a Bigger Opportunity

Tesla Inc (NASDAQ:TSLA) owes its massive market cap to an expectation of future growth that has already been priced into the stock. Much …

DryShips Inc. (DRYS): Red Flags Keep Popping Up

DryShips Inc. (NASDAQ:DRYS) has acquired three second-hand Kamsarmax dry bulk vessels for a total of $68 million.

Alphabet Inc’s (GOOGL) Google Is in a Tough Spot

Tech giant Google, a subsidiary of Alphabet Inc (NASDAQ:GOOGL), is in a public relations nightmare. And this problem will be expensive to fix.

Valeant Pharmaceuticals Intl Inc (VRX) Legal Mess Is An Existential Threat

As if declining EBITDA, political pressure, and debt were not bad enough, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) must contend with the risk of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts